CO7400878A2 - Anticuerpos anti-mcam y métodos de uso asociados - Google Patents

Anticuerpos anti-mcam y métodos de uso asociados

Info

Publication number
CO7400878A2
CO7400878A2 CO15077895A CO15077895A CO7400878A2 CO 7400878 A2 CO7400878 A2 CO 7400878A2 CO 15077895 A CO15077895 A CO 15077895A CO 15077895 A CO15077895 A CO 15077895A CO 7400878 A2 CO7400878 A2 CO 7400878A2
Authority
CO
Colombia
Prior art keywords
mcam
associated methods
mcam antibodies
antibodies
antigen
Prior art date
Application number
CO15077895A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Flanagan
Jeanne Baker
Theodore A Yednock
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CO7400878A2 publication Critical patent/CO7400878A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CO15077895A 2012-09-10 2015-04-08 Anticuerpos anti-mcam y métodos de uso asociados CO7400878A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698916P 2012-09-10 2012-09-10
US201261797179P 2012-11-30 2012-11-30
US201261797356P 2012-12-05 2012-12-05

Publications (1)

Publication Number Publication Date
CO7400878A2 true CO7400878A2 (es) 2015-09-30

Family

ID=50237783

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15077895A CO7400878A2 (es) 2012-09-10 2015-04-08 Anticuerpos anti-mcam y métodos de uso asociados

Country Status (23)

Country Link
US (6) US9447190B2 (enExample)
EP (2) EP2892562B1 (enExample)
JP (1) JP6339574B2 (enExample)
KR (1) KR102194568B1 (enExample)
CN (2) CN105120895A (enExample)
AR (1) AR092488A1 (enExample)
AU (2) AU2013312203B2 (enExample)
CA (1) CA2884463A1 (enExample)
CL (1) CL2015000582A1 (enExample)
CO (1) CO7400878A2 (enExample)
CU (1) CU20150023A7 (enExample)
DK (1) DK2892562T3 (enExample)
EA (1) EA201590528A1 (enExample)
ES (1) ES2718208T3 (enExample)
IL (1) IL237625A0 (enExample)
MX (1) MX2015002918A (enExample)
MY (1) MY182427A (enExample)
PE (1) PE20151286A1 (enExample)
PH (1) PH12015500514A1 (enExample)
SG (2) SG10201708127UA (enExample)
TW (3) TW201922795A (enExample)
WO (1) WO2014039975A2 (enExample)
ZA (1) ZA201501858B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2889377B1 (en) 2012-08-24 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Fcyriib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
EP2982689B1 (en) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
CA2938946A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
JP2017510627A (ja) * 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
WO2016022694A1 (en) * 2014-08-05 2016-02-11 The University Of Chicago Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
CN104725483A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种黑色素瘤细胞粘附分子拮抗剂多肽及其应用
CN104710513A (zh) * 2015-04-06 2015-06-17 苏州普罗达生物科技有限公司 黑色素瘤细胞粘附分子拮抗剂多肽及其应用
JP2018530540A (ja) * 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017046774A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP3387442A4 (en) 2015-12-09 2019-05-08 Corvus Pharmaceuticals, Inc. HUMANIZED ANTI-CD73 ANTIBODIES
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
WO2018223140A1 (en) * 2017-06-02 2018-12-06 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CA3087058A1 (en) * 2017-12-26 2019-07-04 The Regents Of The University Of California Human antibodies that bind and are internalized by mesothelioma and other cancer cells
EP3898964A4 (en) * 2018-12-21 2023-05-24 Multitude Inc. ANTIBODIES SPECIFIC TO MUC18
CN117447599A (zh) 2018-12-21 2024-01-26 普众发现医药科技(上海)有限公司 对muc18特异性的抗体
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1520819A (en) 1976-05-10 1978-08-09 Robertson H J Medical protein hydrolysate process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7192931B2 (en) 2000-10-12 2007-03-20 Neuren Pharmaceuticals Ltd. Treatment of demyelinating diseases
US6866866B1 (en) 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
AU2002252444A1 (en) 2001-03-23 2002-10-08 Board Of Regents, The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
WO2003005783A2 (en) 2001-07-03 2003-01-16 Sciperio, Inc. Methods and systems for embedding electrical components in a device including a frequency responsive structure
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP2005516965A (ja) * 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
ATE394121T1 (de) 2001-12-28 2008-05-15 Amgen Fremont Inc Verwendung von antikörpern gegen das muc18- antigen
DE60220719T2 (de) 2001-12-28 2008-03-06 Amgen Fremont Inc. Antikörper gegen das muc18-antigen
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
EP1551453A4 (en) 2002-06-17 2007-04-25 Us Gov Health & Human Serv SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
WO2004001004A2 (en) * 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
EP1382615A1 (en) * 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
SK50642005A3 (sk) 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
WO2006033702A2 (en) * 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007058725A2 (en) * 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
CN101426815A (zh) * 2005-12-06 2009-05-06 杜门蒂斯有限公司 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
US20120047586A9 (en) 2007-10-24 2012-02-23 Otsuka Chemical Co., Ltd Polypeptide having enhanced effector function
EP2220122A2 (en) * 2007-11-13 2010-08-25 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against tl1a
EP2234600B1 (en) 2007-12-21 2014-08-20 F. Hoffmann-La Roche AG Antibody formulation
US8155019B2 (en) * 2008-01-07 2012-04-10 Canon Kabushiki Kaisha Information processing apparatus, device information display method, and computer-readable storage medium
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
JP5858785B2 (ja) * 2009-07-29 2016-02-10 シスメックス株式会社 ヒトｉｌ−１７産生ヘルパーｔ細胞検出用マーカーおよび試薬、並びにヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法
WO2011100477A2 (en) * 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CN105037543B (zh) 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
CA2802273A1 (en) 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
MX375266B (es) 2010-11-25 2025-03-06 Allecra Therapeutics Gmbh Compuestos y su uso.
JP5946605B2 (ja) * 2011-01-28 2016-07-06 シスメックス株式会社 ヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法
JP6305919B2 (ja) * 2011-06-06 2018-04-04 プロセナ バイオサイエンシーズ リミテッド Ｍｃａｍアンタゴニスト及び治療の方法
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
CA2926089C (en) 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
WO2015136570A1 (ja) 2014-03-11 2015-09-17 パナソニック液晶ディスプレイ株式会社 表示装置及びその駆動方法
US20170101470A1 (en) 2014-03-12 2017-04-13 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US20170129954A1 (en) 2014-03-12 2017-05-11 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
JP2017512772A (ja) 2014-03-12 2017-05-25 プロセナ バイオサイエンシーズ リミテッド Ｌｇ１〜３に特異的な抗ラミニン４抗体
CA2938946A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP2017510627A (ja) 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018223140A1 (en) 2017-06-02 2018-12-06 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Also Published As

Publication number Publication date
KR20150046350A (ko) 2015-04-29
AU2013312203A1 (en) 2015-03-19
PE20151286A1 (es) 2015-10-04
JP6339574B2 (ja) 2018-06-06
SG10201708127UA (en) 2017-11-29
SG11201501773RA (en) 2015-04-29
MY182427A (en) 2021-01-25
AU2018241135B2 (en) 2020-04-16
US10584177B2 (en) 2020-03-10
IL237625A0 (en) 2015-04-30
CU20150023A7 (es) 2016-03-31
KR102194568B1 (ko) 2020-12-28
WO2014039975A2 (en) 2014-03-13
HK1212256A1 (en) 2016-06-10
US20170037144A1 (en) 2017-02-09
US20200216560A1 (en) 2020-07-09
JP2015533795A (ja) 2015-11-26
TWI660972B (zh) 2019-06-01
DK2892562T3 (en) 2019-04-15
TWI595007B (zh) 2017-08-11
ZA201501858B (en) 2016-11-30
CN105120895A (zh) 2015-12-02
US10407507B2 (en) 2019-09-10
WO2014039975A3 (en) 2014-06-05
PH12015500514A1 (en) 2015-04-27
US20180105602A1 (en) 2018-04-19
US20150239980A1 (en) 2015-08-27
EP2892562A4 (en) 2016-05-04
EA201590528A1 (ru) 2015-12-30
TW201809001A (zh) 2018-03-16
US9447190B2 (en) 2016-09-20
TW201922795A (zh) 2019-06-16
EP2892562A2 (en) 2015-07-15
US20170145109A1 (en) 2017-05-25
AU2013312203B2 (en) 2018-07-12
EP2892562B1 (en) 2019-03-06
US20140227292A1 (en) 2014-08-14
MX2015002918A (es) 2015-08-14
CN107266571A (zh) 2017-10-20
ES2718208T3 (es) 2019-06-28
AU2018241135A1 (en) 2018-10-25
CL2015000582A1 (es) 2015-11-06
AR092488A1 (es) 2015-04-22
TW201422639A (zh) 2014-06-16
US10414825B2 (en) 2019-09-17
EP3530287A1 (en) 2019-08-28
CA2884463A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CO7400878A2 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
CO2018006299A2 (es) Compuestos novedosos
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
ECSP12012244A (es) Pirrolobenzodiacepinas y conjugados de las mismas
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
MX2016003744A (es) Anticuerpos tem8 y su uso.
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
EA201400447A1 (ru) АНТИТЕЛА К CD1d
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
AR097038A1 (es) Uso de un ligando de cd6 y método basado en el
MX392348B (es) Anticuerpo anti cd43 y uso del mismo para tratamiento del cáncer.